Bexion Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.bexionpharma.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
- Conditions
- Metastatic Colorectal CarcinomaNeuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT05322590
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸Pacific Hematology Oncology Associates, San Francisco, California, United States
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
- Conditions
- Neuropathy;PeripheralChemotherapy-induced Peripheral Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05291286
- Locations
- 🇺🇸
CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸The Ohio State Unviersity, Columbus, Ohio, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
- Conditions
- Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04771897
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's, Columbus, Ohio, United States
Continued Treatment for Participants Enrolled in Studies of BXQ-350
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04404569
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸University of Cincinnati Barrett Center, Cincinnati, Ohio, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03967093
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's, Columbus, Ohio, United States
- Prev
- 1
- 2
- Next